Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Medicenna Therapeutics Corp stock

Learn how to easily invest in Medicenna Therapeutics Corp stock.

Medicenna Therapeutics Corp is a biotechnology business based in the US. Medicenna Therapeutics Corp shares (MDNA) are listed on the NASDAQ and all prices are listed in US Dollars. Medicenna Therapeutics Corp employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Medicenna Therapeutics Corp

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MDNA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Medicenna Therapeutics Corp stock price (NASDAQ: MDNA)

Use our graph to track the performance of MDNA stocks over time.

Medicenna Therapeutics Corp shares at a glance

Information last updated 2022-06-24.
Latest market close$1.19
52-week range$0.76 - $3.69
50-day moving average $1.03
200-day moving average $1.66
Wall St. target price$7.98
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.36

Buy Medicenna Therapeutics Corp shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
$0
$0
N/A
Financial advice powered by relationships, not commissions.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Medicenna Therapeutics Corp stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Medicenna Therapeutics Corp price performance over time

Historical closes compared with the close of $1.19 from 2022-06-29

1 week (2022-06-23) 11.21%
1 month (2022-05-27) 17.82%
3 months (2022-03-28) -8.46%
6 months (2021-12-30) -28.31%
1 year (2021-06-30) -60.47%
2 years (2020-06-30) -67.22%
3 years (2019-06-28) 5.31%
5 years (2017-06-26) N/A

Medicenna Therapeutics Corp financials

Gross profit TTM $0
Return on assets TTM -50.17%
Return on equity TTM -87.05%
Profit margin 0%
Book value $0.43
Market capitalisation $60.1 million

TTM: trailing 12 months

Medicenna Therapeutics Corp share dividends

We're not expecting Medicenna Therapeutics Corp to pay a dividend over the next 12 months.

Medicenna Therapeutics Corp share price volatility

Over the last 12 months, Medicenna Therapeutics Corp's shares have ranged in value from as little as $0.76 up to $3.69. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medicenna Therapeutics Corp's is 0.4301. This would suggest that Medicenna Therapeutics Corp's shares are less volatile than average (for this exchange).

Medicenna Therapeutics Corp overview

Medicenna Therapeutics Corp. , a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Frequently asked questions

What percentage of Medicenna Therapeutics Corp is owned by insiders or institutions?
Currently 32.957% of Medicenna Therapeutics Corp shares are held by insiders and 6.825% by institutions.
How many people work for Medicenna Therapeutics Corp?
Latest data suggests 13 work at Medicenna Therapeutics Corp.
When does the fiscal year end for Medicenna Therapeutics Corp?
Medicenna Therapeutics Corp's fiscal year ends in March.
Where is Medicenna Therapeutics Corp based?
Medicenna Therapeutics Corp's address is: 2 Bloor Street West, Toronto, ON, Canada, M4W 3E2
What is Medicenna Therapeutics Corp's ISIN number?
Medicenna Therapeutics Corp's international securities identification number is: CA58490H1073

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site